An observational study in Colorectal Cancer (CRC), Microbiome and Early Onset Colorectal Cancer, sponsored by Gulbenkian Institute for Molecular Medicine. Recruiting at 2 sites in Portugal. Open to participants aged 40 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Gulbenkian Institute for Molecular Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Colorectal Neoplasms with a site in Portugal — 8 open to participants now, 15 under way, 6 of them phase 3. Colorectal Neoplasms · Portugal.
Among the 53 studies in Colorectal Neoplasms with a site in Portugal, this one is one of 2 that started in 2026, is one of 8 observational ones, reaches primary completion later than 8 of the 14 other live ones, and was the 51st registered.
6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →8 of the 53 studies in Colorectal Neoplasms with a site in Portugal are open now. Recruiting first, the newest first:
AbbVie · Sites in Portugal, United States, Belgium and 8 more countries
Ages 18+
ADVANCED MARKER DISCOVERY S.L. · Sites in Portugal, Spain
Ages 50–69 · Healthy volunteers
ADVANCED MARKER DISCOVERY S.L. · Sites in Portugal, Spain
Ages 50–69 · Healthy volunteers
Firalis SA · Sites in Portugal, Bulgaria, France and 3 more countries
Ages 18+
Amgen · Sites in Portugal, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 40 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 27
First in 1998; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 250 across 1,444 observational studies indexed under Colorectal Neoplasms.
Median enrollment 680 across the 41 interventional studies, 703 across the 8 observational. Of the 31 that completed or were terminated, 16 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 53 have an industry lead sponsor. The 10 most frequent:
Gulbenkian Institute for Molecular Medicine is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Gulbenkian Institute for Molecular Medicine has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Colorectal Neoplasms with a site in Portugal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06741293Gulbenkian Institute for Molecular MedicineImproving Colorectal Cancer Early Screening in Portugal: Identification of Gut Microbiome Biomarkers in Stool (GUTBIOME-PT) | 2026-11-28 |
| NCT06734156Gulbenkian Institute for Molecular MedicineCARE-CRC: Microbiome Insights and Correlations for Risk and Outcomes in Colorectal Cancer | 2026-12-02 |
| NCT06515821Firalis SAMulticentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 53 studies in Colorectal Neoplasms with a site in Portugal, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths globally, with increasing incidence rates. While predominantly affecting older adults, CRC cases among individuals under 50 (early-onset CRC, or EoCRC) are rising. This age group rarely undergoes routine screening, resulting in delayed diagnoses and more advanced disease at presentation. In the USA, EoCRC accounts for 10% of CRC cases and is the leading cause of cancer-related deaths in men under 50.
Despite the increase in EoCRC incidence, the causes remain unclear. Only 25% of cases have a CRC family history, suggesting environmental factors. Diets low in fibre and rich in fat and red meat, obesity, alcohol consumption, sedentary lifestyle, stress, and chronic inflammation of the GI tract are estimated to account for 70-90% of CRC risk. According to the World Cancer Research Fund, 47% of all CRC cases could be prevented through lifestyle changes, particularly in diet and physical activity.
These lifestyle factors are also strongly linked to changes in the gut microbiome, which differs markedly between CRC patients and healthy individuals. The microbiome may influence tumour development by producing metabolites that regulate immune responses or create anti-tumour environments. Thus, the gut microbiome is a promising target for early CRC detection and prevention.
This study aims to develop a non-invasive, microbiome-based diagnostic tool for CRC, identifying biomarkers to improve early detection, personalise treatment, and reduce healthcare costs.
This study focuses on identifying faecal microbiome biomarkers for CRC across different stages, prognoses, and therapeutic responses, with a particular emphasis on EoCRC. Recruitment will include individuals recently diagnosed with CRC who have not undergone treatment.
Faecal samples will be collected at three key time points:
Baseline - At diagnosis and study entry. Post-Treatment - After completing each therapeutic regimen, such as neoadjuvant chemotherapy, surgery and/or adjuvant chemotherapy Follow-Up - Three years after diagnosis. The study will also monitor survival rates and disease progression over three years.
Primary Objective:
To identify and characterise changes in the gut microbiome at different CRC stages.
Secondary Objectives:
i. Identify faecal microbiome biomarkers associated with CRC overall and stratify findings by age and sex.
ii. Compare microbiome profiles and associated clinical and lifestyle data between CRC patients and healthy controls, stratified by age and sex.
iii. Identify lifestyle and dietary factors contributing to CRC risk, stratified by age and sex.
iv. Validate biomarkers specific to EoCRC. v. Correlate microbiota composition with overall survival. vi. Correlate microbiota composition with disease-free survival.
This is a longitudinal observational study targeting individuals aged 40-74 who have been newly diagnosed with CRC and are treatment-naïve
Patients with all inclusion criteria and none of the exclusion criteria (detailed in the specific section of this website) will be considered for this study. Using a significance level of 5% and a power of 80%, the required sample size is 80 individuals per age group (40-49, 50-59, 60-64, 65-69, and 70-74 years). This results in a total of 400 participants. A control group of healthy individuals will be recruited from hospital patients undergoing routine screening colonoscopies.
Biological and clinical data will be collected at multiple time points throughout the study. Faecal samples will be obtained at baseline, post-treatment, and during the three-year follow-up, accompanied by blood sample collection at each of these time points. Clinical data will include detailed tumour characteristics, such as location, symptoms, and staging, as well as treatment information, including surgery and chemotherapy. Outcomes related to survival and disease progression will also be recorded.
Lifestyle and dietary data will be gathered through self-reported questionnaires capturing demographic factors such as age, smoking habits, physical activity, stress levels, and body mass index (BMI). Dietary habits and adherence to the Mediterranean diet will be assessed via telephone interviews.
The gut microbiome will be profiled using shotgun metagenomic sequencing, enabling the characterisation of microbial species and functional pathways. This analysis will identify potential correlations between microbiome composition and clinical outcomes, including therapeutic responses and survival rates.
For statistical testing, qualitative variables will be analysed using Chi-square or Fisher's exact tests, while quantitative variables will be assessed using Student's t-test or ANOVA. If the normality assumption is not met, Mann-Whitney or Kruskal-Wallis tests will be used. All statistical analyses will be two-sided, with a significance level set at 5%.
Expected Outcomes:
The study aims to identify biomarkers that enable early, non-invasive CRC detection. Findings will also provide insights into the interplay between lifestyle, diet, and microbiome changes in CRC progression. These insights could lead to personalised preventive strategies and improved therapeutic outcomes.
The recruitment for this study will be conducted in close collaboration with the oncology and general surgery departments from partner hospitals. Participants who meet all eligible criteria will be selected and provided with detailed information about the clinical study by study coordinators at each hospital. Those who agree to participate will be required to sign an informed consent form.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with a confirmed CRC diagnosis, stratified by age: 40-49, 50-59, 60-64, 65-69, and 70-74 years.
Other: No intervention: observational study
No intervention: observational study
Microbiome biomarkers associated with CRC.
The faecal microbiome's composition and gene profiles will be analysed using shotgun metagenomic sequencing. Data will be integrated with lifestyle and dietary factors to identify biomarkers linked to CRC stages.
Time frame: Baseline and Follow-up up to 3 years
Microbiome biomarkers associated with EoCRC.
Similar analysis as Outcome number 1, focused specifically on early-onset CRC cases.
Time frame: Baseline and Follow-up up to 3 years
Correlation between microbiome biomarkers and overall survival and disease-free survival.
Biomarkers will be correlated with clinical follow-up data, including overall survival (survivors vs non-survivors) and disease-free progression (relapse vs no relapse).
Time frame: 3 years
Effect of diet on CRC risk and gut microbiota composition
Dietary intake will be assessed via telephone interviews using two 24-hour dietary recalls. These follow protocols validated by the European Food Safety Authority (EFSA) and the Portuguese National Food and Physical Activity Survey (IAN-AF).
Time frame: Baseline
Effect of the Mediterranean Diet (MD) on CRC risk and gut microbiota composition
Adherence to the MD will be assessed with the PREvención con DIeta MEDiterránea (PREDIMED) questionnaire, a validated 14-item tool. Scores (0-14) will categorise adherence as low (\<5), moderate (6-9), or high (\>10).
Time frame: Baseline
Effect of physical activity on CRC risk and gut microbiota composition
Physical activity will be assessed using the Nordic Physical Activity Questionnaire-Short (NAPQ-short) form, which evaluates adherence to WHO physical activity recommendations.
Time frame: Baseline
Effect of sleeping habits on CRC risk and gut microbiota composition
Sleeping habits will be assessed by the Pittsburgh Sleep Quality Index, a validated questionnaire that consists of 19 items which are distributed into seven "components": subjective sleep quality; sleep latency; sleep duration; habitual sleep efficiency; sleep disturbances; use of sleeping medication; day-time dysfunction. Each component is scored from 0 to 2, and the sum of the component scores yields a global PSQI score. A global PSQI score of ≥6 will indicate poor sleep quality.
Time frame: Baseline
Effect of stress levels on CRC risk and gut microbiota composition
Stress levels will be evaluated using the Perceived Stress Scale (PSS), a validated 10-item tool. Scores range from 0-40, categorised as low (0-13), moderate (14-26), or high (27-40).
Time frame: Baseline
Identify and quantity inflammation markers
Blood samples will be collected in K2EDTA tubes and processed for plasma separation. Inflammatory markers, including C-reactive protein and cytokines (e.g., IL-1β, IL-6, TNF-α), will be quantified using ELISA.
Time frame: Baseline and Follow-up up to 3 years
Differential gene expression in tumour samples
For participants undergoing surgery, tumour samples will be collected, preserved, and processed for transcriptomic analysis. RNA extraction will be performed to assess gene expression profiles, with a particular focus on microsatellite instability (MSI) and tumour microenvironment interactions.
Time frame: Baseline
Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.
Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 9 months is below that.
Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gulbenkian Institute for Molecular Medicine